Cytokinetics Inc. CYTK

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

• GlobeNewswire Inc. 2 oct

  Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026

  Cytokinetics announced four presentations at the Heart Failure Society of America Annual Scientific Meeting in October 2026, including two late-breaking clinical research presentations on aficamten (MYQORZO) for hypertrophic cardiomyopathy. The company plans to submit a Supplemental New Drug Application for aficamten in non-obstructive HCM in Q4 2026 following positive Phase 3 trial results.

  

• The Motley Fool 18 sept

  AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

  AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.

  

• Zacks Investment Research 4 sept

  Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?

  Bristol Myers Squibb's Camzyos demonstrated durable reductions in LVOT obstruction over five years with 97.4% of patients achieving target gradients. Sales surged 74% year-over-year to $729 million in H1 2026. The company seeks FDA approval for adolescents with a decision expected by September 30, 2026. However, competition is intensifying with Cytokinetics' Myqorzo approved in December 2025 and Edgewise Therapeutics advancing EDG-7500 in clinical trials.

  

• GlobeNewswire Inc. 2 sept

  Cytokinetics to Participate in September Investor Conferences

  Cytokinetics announced that management will participate in multiple investor conferences in September 2026. The company highlighted positive results from its ACACIA-HCM Phase 3 clinical trial for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM), with plans to submit a Supplemental New Drug Application in Q4 2026. The trial demonstrated statistically significant improvements in both patient-reported and physician-assessed endpoints.

  

• Zacks Investment Research 2 sept

  Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

  Cytokinetics announced additional positive results from ACACIA-HCM and MAPLE-HCM studies showing aficamten improved cardiac structure and diastolic function in non-obstructive HCM patients, and outperformed metoprolol in obstructive HCM. The company plans to file for nHCM approval in Q4 2026, potentially expanding the drug's addressable market. Myqorzo received FDA approval in December 2025 for obstructive HCM treatment.